Skip to main content

Vyepti FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved February 21, 2020)
Brand name: Vyepti
Generic name: eptinezumab-jjmr
Dosage form: Injection
Company: Lundbeck Inc.
Treatment for: Migraine Prevention

Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the prevention of migraine in adults.

Development timeline for Vyepti

Aug 19, 2022Lundbeck's Migraine Drug Hits Roadblock in Phase III
Feb 22, 2020Approval FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine
Jun 27, 2017Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.